H. Jack West, MD, FASCO
@jackwestmd
VP of Clin Development, @SMMT_Tx; Founder,@CancerGRACE; fmr author/ed @UptoDate, fmr Web Ed @JAMAOnc & @MedscapeOnc columnist; Likes/RTs ≠ endorsement
ID: 28943421
http://www.JackWestMD.com 05-04-2009 04:54:07
27,27K Tweet
22,22K Followers
2,2K Following
Honored to be in such an incredible ASCO FASCO Class! Congrats to all & thank you for working to make oncology better for patients, providers, & researchers! 🥰🙌👏💪🧬🩺💊🥼⚕️ Julia Close, MD, MBA Prof Michael Jefford Gretchen Kimmick Mark Lewis, MD, FASCO Ana Maria Lopez, MD, MPH, MACP Maryam Lustberg MD, MPH, FASCO DrKatyMoore
H. Jack West, MD, FASCO U.S. FDA Yes absolutely, that’s the obvious question. I heard a comment saying “We did something before, doesn’t mean we need to do the same mistake again” Regardless, this will come up again with 77T and still may end up with the same fate- then I 🤔what was the point of the ODAC?
#WCLC24 abstract titles released! Don't miss the plenary Sunday September 8th at 8:30am PDT - I am particularly eager to see the ivonescimab vs pembro HARMONi-2 data from Dr. Caicun Zhou, Neocoast-2 from Dr. Tina Cascone, and the 77T vs CM816 analysis from Dr. Patrick Forde!
Our video of the GRACE Spanish Targeted Therapy forum is available online youtube.com/watch?v=M5vqx9… with Ivy Riano, M.D. Dr. Estela Rodriguez Ana I. Velázquez Mañana, MD, MSc, FASCO Claudio Martin Andres F. Cardona #lungcancer #lungcancerawareness #lcsm H. Jack West, MD, FASCO
Oncology Brothers FDA Oncology Bijoy Telivala Santhosh Ambika gilberto lopes H. Jack West, MD, FASCO Narjust Florez, MD, FASCO Charu Aggarwal, MD, MPH, FASCO LUNGevity Foundation Dr. Amy C. Moore part of the toxicity table from the NEJM paper below much higher rate of grade 3 or greater events much higher rate of dose interruption much higher rate of drug discontinuation
Our GRACE Spanish Therapy forum dont miss the presentations cancergrace.org/post/vod-foro-… Ivy Riano, M.D. Dr. Estela Rodriguez Andres F. Cardona Claudio Martin #lungcancer #lcsm